The first Korean botulinum toxin product, Lotte, was approved in China

Recently, Shihuan Pharmaceuticals announced that the "Injected Type A Botulinum Toxin (Letybo 100U, the commodity named Lotte) " produced by the company's sole agent, South Korean biopharmaceutical company Hugel, was officially launched on October 21, 2020. Approved for listing by the State Drug Administration, this is the fourth pharmaceutical company approved in China after U.S. drug companies Eljian, Lanzhou Institute of Biological Products and France's Ipsum, and the first of its kind in South Korea, which is expected to start selling in Chinese mainland within the year.
it is understood that botulinum toxin is commonly known as botulinum toxin, is a terratin-stained positive anaerobic Botox in the reproductive process produced by an exotoxin, with strong neurotoxicity.
in the body, botulinum toxin can interfere with the release of acetylcholine from the ends of motor nerves, blocking the transmission of information between nerves and muscles, so that muscle fibers cannot contract.
In the medical and aesthetic industry, the main application of botulinum toxin is muscle spasms and wrinkle removal, the injection effect is generally maintained for 3-6 months, after the recurrence of wrinkles and muscle enlargement can be re-injected.
Botox has 8 subsypes, the current medical industry is widely used in the A-type injectable botulinum toxin.
statistics show that in 2019, Chinese mainland's botulinum toxin products market size of about US$600 million (about HK$4.66 billion), penetration rate is less than 2% of China's overall medical beauty market, the market still has a large number of unseeded demand.
Sales of Chinese mainland botulinum toxin products are expected to explode over the next five years as the number of Chinese beauty-seekers continues to grow, with sales reaching US$1.8 billion (about HK$13.5 billion) in 2025, making it one of the three largest markets in the world along with the US and the EU.
in Chinese mainland, the relevant state regulatory authorities botulinum toxin products control is very strict, market access threshold is very high, the current approved listed botulinum toxin products only Lanzhou Institute of Biological Products, Aer Jian's Baoyi, and Yipson's Jiji.
Among them, Hengli is the first botulinum toxin product listed in the Chinese market, approved in 1997, the first for the treatment of adult patients such as eyelid spasms, face muscle spasms and some squint patients, and in 2012, expanded to improve the temporary treatment of severe eyebrow tattoos in adults.
price is 240-750 yuan / unit, the target group is mainly middle- and high-end groups. two years after
Hengli went on sale, in 1999, the FDA approved the world's first botulinum toxin product, Prudential, which was approved by China's original CFDA, originally for the treatment of patients with partial side muscle spasms and eyelid spasms, and in 2009, Prudential's adaptive disorder expanded to improve temporary treatment of severe eyebrow lines in adults.
priced at 240-750 yuan/unit, mainly for high-end people.
approved by the State Drug Administration in June, the third type of botulinum toxin to be approved for listing in China.
the approved Lotte in South Korea's local market share of more than 40%, ranking first.
2017, it conducted its third phase of clinical research at Chinese mainland until it was approved today, and Four Rings Pharmaceuticals said in a statement that Letybo 100U expects to achieve double-digit market share in China within three years, becoming Chinese mainland's first tier of sales of botulinum toxin brands.
source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here